Brief: Aligos Therapeutics On Track To Complete Phase 2-Enabling Activities In 2023 For ALG-055009
05/01/2023 14:01
Jan 5 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS ON TRACK TO COMPLETE PHASE 2-ENABLING
ACTIVITIES IN 2023 FOR ITS CLINICALLY VALIDATED THR-ß DRUG
CANDIDATE FOR NASH, ALG-055009
* ALIGOS THERAPEUTICS INC - FINAL COHORT OF PHASE 1 STUDY
PROJECTED TO BE COMPLETE IN H1 2023
* ALIGOS THERAPEUTICS INC - PHASE 2-ENABLING GLP TOXICOLOGY
STUDIES PROJECTED TO BE COMPLETE IN H2 2023
Source text for Eikon: ID:nGNX2CD6sj
Further company coverage: ALGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue